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Abstract
Sir Oliver Scott, a philanthropist and radiation biologist and, therefore, the epitome of a gentleman and a scholar, was
an early Director of the BECC Radiobiology Research Unit at Mount Vernon. His tenure preceded that of Jack Fowler,
with both contributing to basic, translational and clinical thought and application in radiation across the globe. With
respect to this review, Fowler’s name in particular has remained synonymous with the use of models, both animal and
mathematical, that assess and quantify the biological mechanisms that underlie radiation-associated normal tissue
toxicities. An understanding of these effects is critical to the optimal use of radiation therapy in the clinic; however, the
role that basic sciences play in clinical practice has been undergoing considerable change in recent years, particularly
in the USA, where there has been a growing emphasis on engineering and imaging to improve radiation delivery, with
empirical observations of clinical outcome taking the place of models underpinned by evidence from basic science
experiments. In honour of Scott and Fowler’s work, we have taken this opportunity to review how our respective fields
of radiation biology and radiation physics have intertwined over the years, affecting the clinical use of radiation with
respect to normal tissue outcomes. We discuss the past and current achievements, with the hope of encouraging a
revived interest in physics and biology as they relate to radiation oncology practice, since, like Scott and Fowler, we
share the goal of improving the future outlook for cancer patients.

PRESERVING NORMAL TISSUE THROUGH
FRACTIONATION—A BRIEF HISTORY
The history of using fractionation as a regimen for delivering radiation dates back almost to its discovery in 1895.
Although the use of X-irradiation as a treatment for
cancer was begun within months of Roentgen’s announcement,1 there was an almost equally fast appreciation of the
profound detrimental effects that radiation can induce
in involved normal tissues, leading to attempts to reduce
this toxicity by spreading its administration over a more
prolonged period of time.2 However, the seemingly more
pressing goal of curing cancer led radiation practitioners to
wage a philosophical and internecine war over the relative
superiority of using multiple vs a few or single fractions.
This battle continued until the 1930s, when the presentation of empirical clinical findings by Coutard demonstrated
the benefits in normal tissues of, what was then termed,
“protracted fractionation”,3 with these revelations leading
to an almost global move away from the use of large fractions. Ultimately, the combination of radiation’s cytotoxic

effects in tumors, together with the improved normal tissue
safety, has led radiation oncologists to provide treatment
to millions of cancer patients, with approximately 50% of
cases now receiving irradiation at some point during their
therapy.4
However, conventional fractionation regimens fail to
completely eliminate the risk of normal tissue effects, which
can span in levels of detriment from non-lethal end points,
such as skin erythema and cognitive dysfunction, to potentially morbid diseases, such as radiation pneumonitis and
radiogenic secondary malignant tumors. Acceptance of the
risk for some level of normal tissue toxicity is seen when
radiation oncologists use the concept of the “therapeutic
ratio,” which balances the probabilities of tumor cure against
normal tissue injury to guide treatment designs. Interestingly, despite the cumulative and overwhelming volume of
evidence in favor of conventional fractionation, there has
been a persistent effort by some clinicians to minimize the
number of delivered fractions, albeit while maintaining the
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tumoricidal outcome. Thus, in the late 1950s, we saw a physicist,
Larsson, working in collaboration with a neurosurgeon, Leksell,
develop the first gamma knife.5 This technology heralded the
re-emergence of hypofractionation, with even greater interest
being seen in the 1990s when Brenner and Hall, physicists from
Columbia University, published their analysis of observational
findings from prostate trials, suggesting that the α/ß ratio for
prostate tumors was not the high dose normally associated with
a radiation-responsive tumor.6 When this announcement was
quickly followed by supportive observations from pre-START
breast trials,7 radiation researchers were urged to find a biological justification for the use of hypofractionation.
NORMAL TISSUE DAMAGE MODELS—
BIOLOGICAL AND MATHEMATICAL
Surprisingly, the performance of supportive scientific studies has
consistently lagged behind the clinical implementation of novel
irradiation dose and timing regimens. Prior to the 1960s, few
animal studies were performed using multifraction regimens
other than the early French studies performed by Regaud and
Ferroux on ram and rabbit testes,8 which were described in Hall’s
classic textbook,9 a canon for radiation oncology residents in the
USA. Nonetheless, those that were undertaken confirmed the
utility of fractionation as a means of sparing normal tissues from
late, though not early, toxicities.10,11 However, during the 1960s,
in vitro and in vivo laboratory techniques began to catch up
with the clinical empirical observations. Radiation researchers,
often working hand-in-hand with radiation oncology physician–scientists, became increasingly focused on deciphering
the biological effects of radiation at the cellular and subcellular
levels—not only in terms of cell death, but also with respect to
repair mechanisms. Indeed, Fowler and his Gray Lab Research
Group developed multiple in vivo models that were used to assess
the radiation response in normal tissues, including a meticulous
skin reaction system used in pigs and mice,12–19 as well as rodent
models assessing responses in lung,20,21 kidney,22 bladder23–25
and the gastrointestinal tract.26,27 These studies were performed
using single, split and multifraction doses, and the derived data
from this group and others were used to develop various mathematical constructs11 that could potentially predict biological
isoeffective responses in normal tissues and, therefore, provide a
scientific justification for both conventional and altered clinical
fractionation schedules.
It is important to note that the final solution of most, if not all, of
these concepts is predicated on cell death as the major variable
of interest, since that is the desired end point in tumors. Interestingly, although Fowler et al had proposed the linear–quadratic
(LQ) model in the 1960s,28,29 it was not until the 1980s, when
Withers et al replotted isoeffect data using dose per fraction
and demonstrated a differential between the response curves
of acutely vs late responding normal tissues,30,31 that it became
clear that tissues that consist of predominantly slowly proliferating tissues, such as brain,32,33 were more sensitive to changes
in fraction size. Thus, the accumulation of biological data, clinical observations and mathematical modeling finally led to a full
appreciation and scientific recognition that fractionated irradiation was, indeed, a means of sparing critical late tissues.
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The formulae that were derived throughout this period, e.g. the
LQ equation, Ellis’ nominal standard dose,34 and Barendsen’s
extrapolated tolerance dose,35 introduced the radiation world to
terminology that, in essence, constrained the physical process
of DNA damage and, by inference, its biological repair within
arbitrarily applied mathematical constants, including α and ß.
They also established such terms as n, the extrapolation number,
which suggested the apparent necessity for a critical number of
hits within each cell, and D0, the rate of cell loss per Gy. As a
result, since the late 1980s, radiation scientists and clinicians
alike have worked under the overarching concept of early and
late responding tissues, with, in many cases, the dose thresholds for late tissue complications defining clinical organ tolerance and, therefore, radiation treatment design.36 The formulae
were, in general, developed from findings made either in vitro
or in the limited number of highly characterized animal models
developed by Fowler and his peers, and then confirmed through
clinical empirical observation. But in practical terms, the mathematical concepts provided clinicians with a means of quantifying
and, therefore, predicting outcomes from fractionation schedules, particularly through the use of the LQ formulation popularized by Fowler and his peers. Indeed, Fowler elegantly described
the necessary calculations needed to design a successful “altered
fractionation” schema through the combined use of an estimation of tumor biological effective dose (BED), a late complications BED and an acute normal tissue BED, making up what he
described as the “Seven Steps to LQ Heaven”.37
However, despite the availability of these mathematical tools
and the accompanying and significant improvements made by
radiation physicists in therapeutic delivery, problems with radiation-associated normal tissue effects continue to be seen in
patients. Importantly, the overall increases seen in many tumor
control rates has led to growing populations of cancer survivors, so that acute and, even more importantly, late toxicities
that appear in normal tissues have started to take on greater
importance. Long-term issues, such as cognitive dysfunction,
cardiovascular disease, immune disruption, tissue remodeling,
metabolic disorders and second malignant tumors, continue to
haunt cancer survivors long after treatment has discontinued,38–47
especially those treated at a younger age.48–57 Unfortunately,
with the majority of radiation-induced late outcomes, once such
effects become symptomatic, mitigation and/or treatment strategies have proven to have limited efficacy. As a result, radiation
oncologists have continued to explore treatment options, e.g.
through the use of altered fractionation strategies, such as hypofractionation, with some promising results in terms of equivalent
or reduced normal tissue toxicities compared to conventional
fractionation outcomes seen in trials for brain, breast and prostate cancers.58–60 But application of Fowler’s “Seven Steps” to the
described regimens would suggest that these findings are anomalous, bordering on the unbelievable, with respect to the reported
low levels of normal tissue effects.
So, what is happening? Are the physicists and engineers truly
providing radiation oncologists with the means of significantly
reducing normal tissue damage? The use of image-guided
and intensity modulated therapies has undoubtedly increased
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the focus of imposed radiation damage within the intended
target, the tumor, however, in many cases, using these newer
approaches has come at the cost of increased exposure of normal
tissues, albeit at a low dose. In fact, the patient’s whole body can
be bathed in low levels of unwanted stray radiation (about one
1/1000th of the therapeutic dose) that emanate as leakage from
the treatment unit and scatter from the tumor. Given the time
that it takes many late effects to become manifest, it remains
currently unclear whether this low-dose “bath” is simply leading
to a delay in toxicity onset, with unforeseen effects lurking over
the horizon. Therefore, do radiation biologists have either the
wherewithal or resources to provide a greater understanding of
both tumor and normal tissue kinetics following radiation injury
in the context of current clinical practice? And is such work
needed in order to guide further innovation by the radiation
physicists and, once more, provide clinicians with rational and
scientific approaches in their search for more effective treatment
paradigms?
NORMAL TISSUE TOXICITY FROM THE
RADIATION PHYSICIST’S PERSPECTIVE
The successes that have been derived from radiation physics are
readily seen in the clinic in terms of improved tumor outcomes
and a reduction in normal tissue reactions. Indeed, physicists
have provided the means to deliver therapeutic radiation with
millimeter accuracy, thereby reducing normal tissue exposures
through improvements in treatment delivery and planning.
However, conspicuous challenges remain, especially with respect
to radiation-induced toxicities in normal tissues. The prevalence
and diversity of late effects in normal tissues are evident from
numerous epidemiology studies of patients who have received
radiotherapy.61–63 Despite this overwhelming evidence implicating radiation exposure as one of the primary risks associated
with therapy-related late effects, we do not yet routinely calculate, estimate, measure, or report most normal tissue exposures,
even though, from a technical perspective, routine calculations
now appear feasible. Indeed, despite enormous sums of money
being spent on equipment for normal tissue dose reduction, the
medical record of a typical radiotherapy patient is devoid of reliable out-of-field exposure data.
How did this situation come to be? Interestingly, we find analogies in military theory. Perusing the respective literatures reveals
the use of similar terminologies: we speak of the “war” on cancer,
precision interventions, surgical strikes, targets, and collateral
damage. Indeed, the similarities in approaches between the wars
waged on cancers and on sovereign states are profound. In his
book entitled “The Art of War”,64 Sun Tzu, a soldier and scholar
of ancient China, laid out the basic principles of war. Although
Tzu’s preferred strategy was prevention, when facing lethal threats
where prevention was not feasible, he recommended using
just enough force to accomplish the objective, thereby limiting
collateral damage to the minimum possible amount, believing
that this usually leads to a superior strategic outcome. Today, our
military and cancer armamentaria are arbitrarily lethal, so that
their application should require a greater consideration of their
potential to cause collateral damage. However, now, as in ancient
times, the neutralization of threats garners more attention than
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the prevention of collateral damage, creating an imbalance in the
therapeutic ratio.
The logic of this argument is strong and compelling for both
kinds of “war”. In both endeavors, the instinctual response clearly
favors action leading to survival of the most immediate existential threat. Furthermore, procurement of any type of expensive
equipment requires significant financial backing and, therefore,
justification is usually based on positive arguments (e.g. suitability for purpose; potential for success) and not on negative
detractors (e.g. uncertain outcomes; collateral consequences).
Psychologically, we also are more prone to focus on our own
beneficence (e.g. saving someone from certain death) rather than
on some vague risk of the unintended harm our actions may
cause decades hence. Taken together, it could be argued that that
these reasons comprise a solid rationale to continue focusing
most of our attention on controlling primary cancers. However,
to do so would be wrong, since this ignores the long history of
treatment advancement made through the collaborative efforts
of radiation physicists, oncologists and biologists. Perhaps, the
most practical and compelling reason to increase research on late
effects is that it will almost certainly lead to better outcomes for
long-term survivors, i.e. fewer and less severe side effects from
radiation therapy. Another reason is the burgeoning population
of long-term cancer survivors, a population projected to swell
to 18.1 million in the USA by 2020, a 30% increase since 2010.65
Already, for some types of childhood cancer, second cancers
cause more deaths than primary tumors,66 with effects such as
cognitive deficits,67,68 cardiovascular disease69,70 and skeletal
abnormalities71–73 causing profound and permanent detriments,
limiting not only quality of life, but leading to long-term employment, insurance and care issues.74 Thus, even at the financial
level, economists would point out that a reduction in the prevalence of late effects would reduce healthcare costs. Notwithstanding, ethical and, perhaps, even legal arguments could be
made that healthcare practitioners have a duty of care to avoid
any needless exposure of healthy tissues.
A first step toward avoiding such exposures is to understand the
prevalence and risk of poor outcomes.75 Quantification requires
more research in the form of long-term clinical trials with normal
tissue effects as a primary end point;76 unfortunately, even
ignoring the low probability of such trials, the inherent delay in
patient presentation of late toxicities means that it will be a long
time, perhaps decades, before the results of such studies could
be accumulated and analyzed with statistical certainly. Until
then, it appears necessary to formulate parallel approaches, by
expanding the scope of radiation treatment planning to include
an assessment of risk of late effects. Currently, these risks are not
routinely determined, mainly because radiation exposures to
most of the normal tissues outside the treatment region are rarely
calculated and recorded. Specifically, clinical treatment planning
systems do not accurately calculate exposure, if at all, outside the
high-dose “irradiated volume”, where, indeed, the vast majority
of second cancers ultimately appear.77,78 New models and algorithms for such calculations are being developed.79–81 Importantly, the prospective adoption of such capabilities at only a few
major cancer centers would dramatically accelerate collection
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of the high-quality dosimetry data that is needed to improve
current radiation risk models.
Despite the projections for impact on cancer survivors suggesting
that the duty of care should increasingly attend to managing
risks of collateral damage, scientifically, the routine assessment
of exposure and risk are conspicuous by their absence. Prior to
the early 2010’s, one could reasonably argue that the lack of this
capability was justified by a combination of factors: modeling
radiation exposures was difficult; stray exposures are deemed
clinically insignificant; and the uncertainties in predicted
outcomes are excessive. However, since that time, the ability to
routinely assess exposures has become eminently more feasible
for advanced technology radiotherapies,80 including proton- and
photon-beam treatments and, indeed, has been implemented in
non-clinical treatment planning systems. Although the uncertainties in predicting risks of a late effect for an individual patient
remain relatively large, especially when the exposure includes
neutrons, several studies now have shown that these uncertainties are manageable for comparing risks to the same patient from
multiple candidate treatments.82
In the broader context, the realm of normal tissue risk assessment has expanded rapidly in the past decade. The basic physics
needed for exposure assessment is, for all intents and purposes,
fully understood. However, much work is still needed to refine,
generalize, and translate exposure models, as well as to integrate
all of the necessary attending technologies (e.g. integration into
the electronic medical record).83 Of the open scientific questions
in this field, those in radiation physics will likely be answered
sooner and more fully, necessarily so, since they are needed in
order to characterize the physical parameters found in radiation
biology and epidemiology studies, which are the more difficult
and lengthy in nature. However, it remains to be seen if the radiation research and medical communities will revise their agendas
to deal effectively with the increasing prevalence of radiation late
effects. Indeed, history suggests that the significant progress that
is needed to reduce collateral damage will be slow and difficult.
NORMAL TISSUE TOXICITY FROM THE
RADIATION BIOLOGIST’S PERSPECTIVE
Radiation biologists (and biophysicists, such as Fowler) have
contributed to the successes seen by their physics and clinical
counterparts, by enabling a greater understanding of the biological effects of treatment parameters, such as dose and fractionation. However, as with the physicists, the biologists have failed in
their goal to fully realize the beneficial potential of radiotherapy
by focusing predominantly on deciphering the effects of radiation
on tumors. As a consequence, our understanding of the effects
of radiation treatment parameters on normal tissues continues
to lag behind. It must be acknowledged that there have been
chronic and significant limitations placed on bench scientists in
this field.84,85 For example, the majority of in vivo studies make
use of single doses—partly due to time (funding) constraints and
the need to establish a robust end point—limiting the clinical
relevance of their findings. Nonetheless, many funding agencies have shown little interest in covering the inherently more
expensive fractionation studies, given the long periods of animal
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housing and care that are required and limited number of institutions that were capable and/or willing to provide the necessary
radiation facilities for such work.37
But another, possibly related, factor that may now be curtailing
the application of radiation biology to the clinic is the increased
insular mentality of its practitioners. As Fowler freely acknowledged, his work over the decades built on that of his predecessors
and peers.37 However, nowadays, the competition for limited
funding has led many laboratories to work in isolation, resulting
in a loss of momentum and progress in normal tissue research.
Indeed, the majority of work currently being performed in this
field makes use of the same biological and mathematical models
developed in the 1980s and 1990s. This is despite recurring
national and international discussions as to the relevance of these
models to the clinical situation,86,87 discussions that have encompassed the applicability of many species to human pathology,88,89
the utility and relevance of inbred vs outbred vs genetically-modified strains,90,91 and the ability and accuracy of applying and
extrapolating data derived from animal models to humans etc.
For example, as with patients, heterogenic responses can be
seen, even within inbred strains, with the timing and severity
of events being strain, age, sex, dose and volume dependent.92,93
Valid arguments can be made to use larger animals that better
predict human responses, such as rabbits, dogs, pigs, and sheep,
however, the costs involved in using statistically appropriate
numbers in terms of purchase and housing, as well as significant animal rights issues, have precluded the use of many of these
species in most institutions. Finally, correlations to the clinic
have been limited by not only the inability of most researchers
to deliver small, clinically-relevant radiation volumes to animal
models, especially rodents,94 but also by a paucity of sufficiently
refined imaging tools that can detect pathological changes in
small volumes of tissue. This situation has begun to improve in
the last decade through the development of small animal radiation research platforms94 and more refined imaging tools, such
as microCT/PET and 2-photon imaging.
Despite these roadblocks, progress is beginning to be made
towards a more thorough understanding of normal tissue radiation biology. Pathological and physiological radiation responses
have been cataloged in animal models,90,95,96 with tissue and
organ differences identified between models.89 Significantly,
beyond the induction of immediate or acute cell death, the
response to radiation injury in normal tissues is now seen as a
highly complex series of events,97,98 with the outcome, unlike that
seen in the tumor, being only partially predicated on cell loss.99 In
addition to the physiology and architecture of the injured organ,
patient-relevant characteristics, such as age and sex, as well as
radiation parameters, such as quality, dose and volume, also
affect the induction and progression of normal tissue effects.99 As
a result, these effects are now considered by many to be the result
of not only the immediate canonical reaction to cell loss, but also
a chronic disruption in homeostatic conditions, resulting in the
dysregulated wound response that characterizes radiation-associated diseases.100–102 The affected homeostatic conditions
include, but are not limited to, immune status, vascular integrity, signaling (cytokine) milieu and oxidative stress levels, with
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disruption in any or all contributing to microenvironmental
degradation and inhibiting the innate compensatory forces that
normally terminate the injury response process.
Although the importance of each homeostatic process differs
between organs due to the spectrum of functions and pathologies, it should be readily apparent that multiple and, likely,
organ/tissue specific approaches are needed to prevent or treat
such dysregulation. Interestingly, many of these same conditions
that are induced by radiation in the normal tissues are present
within the tumor microenvironment and are part of the survival
apparatus that leads to tumorigenesis.100,103,104 This suggests
that the two fields of tumor and normal tissue radiation biology
overlap to a greater degree than has been appreciated to date
and, furthermore, that care needs to be taken that the deliberate
alteration of one microenvironment does not adversely affect the
other in terms of treatment outcome. Indeed, much of the early
work performed in tumors, such as that done in the area of the
oxygen effect by Scott and others,105–107 may now find greater
resonance with normal tissue researchers and suggest “new”
avenues of exploration.
The significant increase in number of contributing factors that
are known now to be involved in normal tissue radiation biology
suggests that most, if not all, of the mathematical concepts used
to date fail to adequately accommodate the potential range of
involved pathways. Greater scrutiny is needed to characterize,
both quantitatively and qualitatively, the roles played by the
tumor and normal tissue microenvironments in the downstream
responses to radiation therapy, assessing both independent and
interactive conditions. Furthermore, the likely need for developing new animal models should include the combined regimens commonly used in the clinic.
CONCLUSIONS
Despite the progress that has been made in the use of radiation
therapy as a treatment modality, to a certain extent, oncologists
are still being faced with the fundamental components of the
therapeutic ratio: developing treatment strategies that balance
tumor cure against the risk of normal tissue injury. However, at
the risk of oversimplification, it would appear that, until recently,
although poor survival rates have tended to drive up prescribed
doses in radiation therapy, malpractice lawsuits, certainly within
the USA, have tended to drive them down. So, to which side of
the therapeutic ratio should we lean? Currently, the competing
legal and medical factors strongly govern the increase being
seen in treatment doses. However, the growing cancer survivor
population is increasingly demanding better outcomes, over and
above a cure of their tumor, especially with regard to quality

of life issues. In order to respond, new approaches are needed
that incorporate a reduction in normal tissue complication
rates beyond those achieved through field size modulation. The
advances being made across all scientific disciplines makes it
clear that the successful interrogation of these complex radiation
effects, including cognitive dysfunction, immune disruption,
tissue remodeling etc. will require the incorporation of expertise
from other, more specialized fields, such as neurobiology, immunology, vascular biology. However, although such an initiative
should broaden the avenues of exploration and increase the
probability of gaining a deeper understanding of radiation-induced normal tissue injury, care must be taken to ensure a
mutual exchange of knowledge and training between disciplines,
otherwise this approach may further dilute the currently limited
resources available to radiation biology and physics researchers
alike by diverting funds to better known and resourced scientists.
We firmly believe that, as in the past, strong collaborations
between radiation biologists and physicists and other members
from ancillary scientific disciplines will lead to new and
improved means of treating cancer patients with higher efficacy and lower risk. However, to create these teams, greater
investment will have to be made on both “sides” of the therapeutic ratio equation, and scientific integration needs to be
encouraged between the involved disciplines. Examples of such
avenues might include radiation biologists and oncologists
working together, to firstly identify pre-treatment biomarkers
that differentiate the downstream radiation responses of tumors
from normal tissues, then working with physicists to target
those cells through the use of current and emerging diagnostics and therapeutics, including imaging and nanotechnology
delivery systems. To reduce the risks of late effects, such as
secondary malignant tumors, the changes in current modeling
paradigms being proposed by medical physicists75 might take
greater account of the biological variables being identified at the
genomic and proteomic levels, so that the potential for personalized treatment planning finally can be realized. However,
such efforts will require a fundamental change in current
thinking, not only by promoting increases in basic and translational funding opportunities, but also at the institutional level,
through active encouragement of collaboration and innovation. Importantly, there needs to be a return to the overarching
philosophy that was the foundation of the work performed by
such as Fowler and Scott: that it is only when the various arms
of radiation research work together, acknowledging and appreciating our respective contributions, that our community can
truly rise to the challenge of improving patient outcomes, not
only with respect to the treatment of their cancers, but assuring
them a full and productive life thereafter.
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